Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialDavid E. Kandzari, Denise Reedus, Jiro Aoki et al.|The Lancet|2018Cited by 775
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialRaymond R. Townsend, Felix Mahfoud, David E. Kandzari et al.|The Lancet|2017Cited by 734
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialMichael Böhm, Benjamin Blossom, Kazuomi Kario et al.|The Lancet|2020Cited by 586
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trialFelix Mahfoud, Michael Böhm, David E. Kandzari et al.|The Lancet|2022Cited by 282
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementVasilios G. Athyros, Christos S. Mantzoros, Theodore K. Alexandrides et al.|Metabolism|2017Cited by 251